Co-diagnostics CODX 深 滬
等待開盤 09-25 09:30:00 美东时间
1.15
+0.050
+4.55%
華盛通- 最 高1.17
- 今 開1.11
- 成交量 41.89万股
- 最 低 1.09
- 昨 收 1.10
- 總市值 802.85万
- 52周最高 13.54
- 市盈率 靜 --
- 換手率 6.00%
- 52周最低 0.9057
- 委 比 99.34%
- 總股本 698.13万
- 歷史最高 13.54
- 量 比 1.47
- 振 幅 7.27%
- 歷史最低 0.9057
- 每 手 1
- 風險率 1.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Co-Diagnostics partners on blood-based PCR Ebola testing
Co-Diagnostics ( ($CODX) ) has issued an update. On September 16, 2026, Co-Diag...
09-16 22:59
Co-Diagnostics to Hold Press Conference
Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m. ET SALT LAKE CITY, Sept. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX...
09-16 04:15
Co-Diagnostics Enters Material Transfer Agreement With ReadyGo Diagnostics To Evaluate Sample Preparation Technologies For Co-Dx PCR Platform; Material Transfer Agreement Does Not Obligate Either Party To Enter Into Any Development, Supply, Commercialization Or Other Commercial Arrangement
In August 2026, Co-Diagnostics, Inc. (the "Company") entered into a material transfer agreement with ReadyGo Diagnostics Ltd ("ReadyGo") to evaluate the potential compatibility of certain ReadyGo sample collection and preparation technologies with the Company’s Co-Dx PCR platform. ReadyGo develops...
09-16 04:10
Co-Diagnostics CFO Brian Brown Departs Company; Appoints Daniel Bohrer As Principal Financial Officer, Effective September 2, 2026
On September 2, 2026, Co-Diagnostics, Inc. (the "Company") and Brian Brown, the Company’s Chief Financial Officer, determined that Mr. Brown’s last day of employment with the Company would be September 2, 2026 (the "Separation Date"). Mr. Brown served as the Company’s principal financial officer and...
09-05 04:40
Co-Diagnostics Adjourns Annual Meeting, Sets New Date
Co-Diagnostics ( ($CODX) ) just unveiled an announcement. Co-Diagnostics, Inc. ...
09-04 21:28
Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
Localized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /P...
09-03 21:00
Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/...
08-18 21:30
Co-Diagnostics Q2 EPS $(1.46) Beats $(3.00) Estimate, Sales $166.131K Miss $166.500K Estimate
Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst consensus estimate of $(3.00) by 51.33 percent. This is a 78.84 percent increase over losses of $(6.90) per share from the same period last year. The company reported quarterly sales of $166.131 thousand ...
08-14 04:04
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings SALT LAKE CITY, Aug. 6, 2026 /PRNewsw...
08-06 21:30
Co-Diagnostics Amends Equity Distribution, Extends Issuance Limits
Co-Diagnostics ( ($CODX) ) just unveiled an announcement. On July 27, 2026, Co-...
07-28 05:29
